Mechanistic insight into antiretroviral potency of 2'-deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a long-lasting effect on HIV-1 prevention.

In preclinical and Phase I and II clinical studies, 2'-deoxy-2'-β-fluoro-4'-azidocytidine (FNC) displays a potent and long-lasting inhibition of HIV-1 infection. To investigate its mechanism of action, we compared it with the well-documented lamivudine (3TC). Pharmacokinetic studies revealed that the intracellular retention of FNC triphosphate in PBMCs was markedly longer than that of 3TC triphosphate. FNC selectively enters and is retained in HIV target cells, where it exerts long-lasting prevention of HIV-1 infection. In addition to inhibition of HIV-1 reverse transcription, FNC also restores A3G expression in CD4+ T cells in FNC-treated HIV-1 patients. FNC binds to the Vif-E3 ubiquitin ligase complex, enabling A3G to avoid Vif-induced ubiquitination and degradation. These data reveal the mechanisms underlying the superior anti-HIV potency and long-lasting action of FNC. Our results also suggest a potential clinical application of FNC as a long-lasting pre-exposure prophylactic agent capable of preventing HIV infection.

[1]  G. Jiang,et al.  Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections. , 2019, Antiviral research.

[2]  R. Gupta,et al.  The Impact of HIV-1 Drug Escape on the Global Treatment Landscape. , 2019, Cell host & microbe.

[3]  E. Arts,et al.  Role of co-expressed APOBEC3F and APOBEC3G in inducing HIV-1 drug resistance , 2019, Heliyon.

[4]  T. Rana,et al.  HIV-1 Escape from Small-Molecule Antagonism of Vif , 2019, mBio.

[5]  L. Fantuzzi,et al.  APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz , 2018, Front. Immunol..

[6]  Zhenlong Liu,et al.  Identification of small molecule compounds targeting the interaction of HIV-1 Vif and human APOBEC3G by virtual screening and biological evaluation , 2018, Scientific Reports.

[7]  M. Murray,et al.  A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population , 2018, Infectious Diseases and Therapy.

[8]  HaroldC. Smith,et al.  A New Class of Antiretroviral Enabling Innate Immunity by Protecting APOBEC3 from HIV Vif-Dependent Degradation. , 2018, Trends in molecular medicine.

[9]  D. Harki,et al.  APOBEC Enzymes as Targets for Virus and Cancer Therapy. , 2017, Cell chemical biology.

[10]  Yong-tang Zheng,et al.  Design, synthesis and biological evaluation of indole derivatives as Vif inhibitors. , 2017, Bioorganic & medicinal chemistry letters.

[11]  Yong-tang Zheng,et al.  Anti-HIV Activities and Mechanism of 12-O-Tricosanoylphorbol-20-acetate, a Novel Phorbol Ester from Ostodes katharinae , 2017, Molecules.

[12]  Yong-tang Zheng,et al.  Synthesis, biological evaluation and molecular docking study of N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif antagonists. , 2017, European journal of medicinal chemistry.

[13]  R. Ptak,et al.  An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation. , 2016, Antiviral research.

[14]  K. A. Ahmed,et al.  Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G , 2016, Journal of Virology.

[15]  S. Sarafianos,et al.  Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) , 2016, Proceedings of the National Academy of Sciences.

[16]  Erez Pery,et al.  Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1. , 2015, Virology.

[17]  T. Pan,et al.  Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex. , 2015, Antiviral research.

[18]  Marc-André Langlois,et al.  Comparative analysis of the gene-inactivating potential of retroviral restriction factors APOBEC3F and APOBEC3G. , 2015, The Journal of general virology.

[19]  Junbiao Chang,et al.  Design, synthesis, and biological evaluation of new N(4)-Substituted 2'-deoxy-2'-fluoro-4'-azido cytidine derivatives as potent anti-HBV agents. , 2015, European journal of medicinal chemistry.

[20]  Jie Wu,et al.  Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection. , 2015, Journal of medicinal chemistry.

[21]  A. Ryo,et al.  ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction , 2015, Nature Communications.

[22]  Kazuyuki Aihara,et al.  APOBEC3D and APOBEC3F Potently Promote HIV-1 Diversification and Evolution in Humanized Mouse Model , 2014, PLoS pathogens.

[23]  Junbiao Chang,et al.  Quantification of 2'-deoxy-2'-β-fluoro-4'-azidocytidine in rat and dog plasma using liquid chromatography-quadrupole time-of-flight and liquid chromatography-triple quadrupole mass spectrometry: Application to bioavailability and pharmacokinetic studies. , 2014, Journal of pharmaceutical and biomedical analysis.

[24]  Junbiao Chang,et al.  Azvudine, A Novel Nucleoside Reverse Transcriptase Inhibitor Showed Good Drug Combination Features and Better Inhibition on Drug-Resistant Strains than Lamivudine In Vitro , 2014, PloS one.

[25]  L. Chelico,et al.  Different Mutagenic Potential of HIV-1 Restriction Factors APOBEC3G and APOBEC3F Is Determined by Distinct Single-Stranded DNA Scanning Mechanisms , 2014, PLoS pathogens.

[26]  Yi Zang,et al.  Structural basis for hijacking CBF-β and CUL5 E3 ligase complex by HIV-1 Vif , 2014, Nature.

[27]  Robert Blumenthal,et al.  Mapping the Vif-A3G interaction using peptide arrays: a basis for anti-HIV lead peptides. , 2013, Bioorganic & medicinal chemistry.

[28]  J. Wedekind,et al.  Core-binding factor β increases the affinity between human Cullin 5 and HIV-1 Vif within an E3 ligase complex. , 2012, Biochemistry.

[29]  Hanna Wójtowicz-Rajchel.  Synthesis and applications of fluorinated nucleoside analogues , 2012 .

[30]  Weidong Hu,et al.  Synthesis of new 2'-deoxy-2'-fluoro-4'-azido nucleoside analogues as potent anti-HIV agents. , 2011, European journal of medicinal chemistry.

[31]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[32]  Hong Cao,et al.  Small-molecule inhibition of HIV-1 Vif , 2008, Nature Biotechnology.

[33]  P. Bieniasz,et al.  Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. , 2006, Virology.

[34]  Xianghui Yu,et al.  Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. , 2004, Genes & development.

[35]  D. Ouyang,et al.  Site-directed PEGylation of trichosanthin retained its anti-HIV activity with reduced potency in vitro. , 2004, Biochemical and biophysical research communications.

[36]  Yunkai Yu,et al.  Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex , 2003, Science.

[37]  Hui Zhang,et al.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA , 2003, Nature.

[38]  Gersende Caron,et al.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts , 2003, Nature.

[39]  M. Malim,et al.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.

[40]  H. Ohrui,et al.  4'-C-substituted-2'-deoxynucleosides: a family of antiretroviral agents which are potent against drug-resistant HIV variants. , 2001, Current drug targets. Infectious disorders.

[41]  M. Matsuoka,et al.  Syntheses of 4‘-C-Ethynyl-β-d-arabino- and 4‘-C-Ethynyl-2‘-deoxy-β-d-ribo-pentofuranosylpyrimidines and -purines and Evaluation of Their Anti-HIV Activity , 2000 .